High sensitivity C protein as an independent risk factor in people with and without history of cardiovascular disease

• Published in: Archivos de cardiologia de Mexico Vol. 85; no. 2; p. 124
• Main Authors: Brito, Viviana, Alcaraz, Andrea, Augustovski, Federico, Pichón-Riviere, Andrés, García-Martí, Sebastián, Bardach, Ariel, Ciapponi, Agustín, Lopez, Analía, Comandé, Daniel
• Format: Journal Article
• Language: Spanish
• Published: Mexico 01.04.2015
• Subjects: Cardiovascular Diseases - blood; Humans; Protein C - analysis; Risk Factors; Sensitivity and Specificity; Myocardial infarction; Argentina; Stable coronary disease; Cardiovascular risk factors; Angina inestable; Factores de riesgo cardiovascular; Ultrasensitive C-reactive protein; Unstable angina; Enfermedad coronaria estable; Infarto de miocardio; Proteína C reactiva ultrasensible
• ISSN: 1665-1731
• DOI: 10.1016/j.acmx.2014.11.005

Among the new cardiovascular event (CVE) risk biomarkers, C-reactive protein detected using high sensitive techniques (hs-CRP) has been one of the most commonly evaluated. In this review, the available evidence on the usefulness of hs-CRP was explored as an independent risk event factor in subjects with no cardiovascular history and as prognosis in case of chronic or acute cardiovascular condition. An overview (revision of revisions) was carried out searching in the main bibliographic databases and in other general Internet search engines. During the first stage, systematic reviews, clinical practice guidelines, health technology assessments and coverage policies were found and, during the second stage primary studies published after the systematic review search dates were added. Seven hundred and seventy four quotes were found, including 36 papers assessing the role of hs-CRP in healthy populations or with cardiovascular history. High quality evidence was found pointing out hs-CRP, both as risk factor in the general population and as prognostic factor in those with CVE, in all the populations assessed. It was most useful in subjects with a history of CVE and intermediate risk of events at 10 years; where adding hs-CRP to the classical models for event risk estimation improves risk staging. There was no consensus on its clinical usefulness as a prognostic marker in subjects with chronic or acute disease.